To Our Shareholders and Investors

• April 16, 2024

  R & D
  Nippon Shinyaku Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW PDF282 KB
• April 04, 2024

  R & D
  Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System PDF266 KB
• March 26, 2024

  Pharmaceuticals
  Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan PDF297 KB
• March 26, 2024

  Pharmaceuticals
  UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan PDF303 KB

IR Calendar

• May 28, 2024

  7th Five-Year Medium-term Management Plan Meeting

• May 14, 2024

  IR Meeting(Q4/FY2023)

• May 10, 2024

  FY2023 Annual results announcement

• February 09, 2024
  Conference Call(Q3/FY2023) PDF2.9 MB
• February 09, 2024
  FY2023 3rd Qtr results announcement PDF679 KB